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IMPORTANCE—Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with 
colon cancer has been shown to provide significant but modest absolute benefit for disease-free 
survival. However, acute and chronic neurotoxic effects from this regimen underscore the need for 
markers that predict oxaliplatin benefit.
OBJECTIVE—To test our hypothesis that molecular subtypes of colon cancer would be 
associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus 
leucovorin therapy.
DESIGN, SETTING, AND PARTICIPANTS—Participants in the NSABP C-07 trial were 
divided into discovery (n = 848) and validation (n = 881) cohorts based on the order of tissue 
block submission. A reestimated centroid using 72 genes was used to determine Colorectal Cancer 
Assigner subtypes and their association with oxaliplatin benefit in the discovery cohort. The 
validation cohort was examined with a locked-down algorithm for subtype classification and 
statistical analysis plan. Post hoc analysis included examination of the entire cohort with 
Colorectal Cancer Assigner, Colorectal Cancer Subtype (CCS), and Consensus Molecular Subtype 
(CMS) methods.
INTERVENTIONS—Fluorouracil plus leucovorin with or without oxaliplatin.
MAIN OUTCOMES AND MEASURES—Percent recurrence-free survival.
RESULTS—Among 1729 patients, 744 (43%) were female and mean (SD) age was 58 (11) 
years. Although C-07 participants with stage III disease with an enterocyte subtype showed a 
statistically significant benefit from oxaliplatin in the discovery cohort (hazard ratio, 0.22 [95% 
CI, 0.09–0.56]; P = .001 [N = 65]), no statistically significant benefit was observed in the 
validation cohort (hazard ratio, 0.53 [95% CI, 0.22–1.24]; P = .14 [N = 70]). The stemlike subtype 
was associated with poor prognosis and lack of benefit from oxaliplatin treatment (HR, 0.99 [95% 
CI, 0.73–1.34]; P = .96 [N = 367]). Examination of the different subtyping methods shows that all 
3 methods robustly identified patients with poor prognosis (stemlike, CCS-3, and CMS-4) in both 
stage II and III.
CONCLUSIONS AND RELEVANCE—Patients with stemlike tumors may be appropriate for 
clinical trials testing experimental therapies because stemlike tumors were robustly identified and 
associated with a poor prognosis regardless of stage or chemotherapy regimen. The clinical utility 
of using subtyping for the identification of patients for treatment with oxaliplatin requires 
validation in independent clinical trial cohorts.
TRIAL REGISTRATION—clinicaltrials.gov Identifier: NCT00004931
The MOSAIC1 and National Surgical Adjuvant Breast and Bowel Project (NSABP) 
C-07/NRG Oncology (referred to hereafter as NSABP C-07)2 clinical trials showed that 
oxaliplatin added to fluorouracil and leucovorin therapy significantly improved disease-free 
survival (DFS) and established oxaliplatin as part of the standard of care for the adjuvant 
treatment of patients with early-stage colon cancer. Patients treated with the addition of 
oxaliplatin in the NSABP C-07 trial showed superior DFS (hazard ratio [HR], 0.80 [95% CI, 
0.69–0.93]; P = .002). However, the acute and chronic neurotoxic effects associated with 
exposure to oxaliplatin3 emphasize the importance of prospectively identifying patients who 
will benefit from oxaliplatin therapy so that patients can avoid adverse effects of a 
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noneffective treatment. Likewise, it is clinically meaningful to identify patients who do not 
receive benefit from oxaliplatin despite a poor prognosis, because they represent the ideal 
candidates for clinical trials testing experimental therapeutics. However, previous efforts to 
develop a predictive test for these patients using gene expression or mutation profiling have 
been unsuccessful.4,5
Recently, several studies6–9 have used unsupervised clustering methods to develop genomic 
signatures to classify colorectal cancer (CRC) into different subtypes and have shown that 
each subtype has distinct molecular features and prognosis. Different studies have identified 
different numbers of clusters, presumably due to using different methods and training data 
sets. For example, the CRC Assigner (CRCA) classifier categorized CRC into 5 distinct 
subtypes: enterocyte, gobletlike, inflammatory, stemlike, and transit amplifying (TA)7; and 
the Colon Cancer Subtypes (CCS) classifier identified 3 groups: CCS1, CCS2, and CCS3.6 
Several studies have shown that different classifiers are highly correlated; for example, for 
CCS and CRCA classifiers, most CCS1 tumors are classified as TA or enterocyte, most 
CCS2 tumors are classified as inflammatory and gobletlike tumors, and most CCS3 tumors 
are classified as stemlike tumors.10,11 Different subtypes were also shown to have different 
prognosis. Particularly, stemlike or CCS3 subtypes are associated with high risk of relapse 
despite fluorouracil-based chemotherapy.6
On the basis of biological differences among identified subtypes, we hypothesized that 
colorectal subtypes would differ in residual risk after fluorouracil-leucovorin adjuvant 
chemotherapy and the degree of benefit derived from the addition of oxaliplatin in NSABP 
C-07. The C-07 tumor samples were classified into CCS6 and CRCA subtypes7 and tested 
for their association with prognosis and interaction with oxaliplatin.
Methods
Study Participant Protection
The institutional review board (IRB) of record for the C-07 clinical protocol with embedded 
tissue banking and molecular profiling studies was the Allegheny-Singer Research Institute, 
and local IRBs approved the C-07 protocol at the enrolling sites. The molecular profiling 
study itself was considered to be exempt by the Chesapeake IRB. All patients included 
signed informed consent for biomedical research using archived tumor tissue. All assays 
were performed by investigators blinded to clinical outcome using deidentified specimens. 
All merged data sets containing clinical and molecular data were anonymized by an honest 
broker.
Initiated in 2000, NSABP C-07 was closed to follow-up in 2012 and included 2370 eligible 
patients with consent and follow-up. This study included 1729 cases with a median follow-
up of 10.22 (interquartile range, 9.5–11.2) years. Clinical variables were well balanced 
between the 2 populations (eTable 1 in the Supplement).
Study Design
We followed the principle of “prospectively designed retrospectively tested” according to 
Simon et al12 with a locked-down algorithm for subtype classification and prespecified 
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direction of interaction of subtypes with oxaliplatin as shown in Figure 1. To test whether 
molecular subtypes are predictive of oxaliplatin benefit, the entire data set was split into 
discovery and validation cohorts of similar sample size. For historical reasons (details in 
eMethods 1 in the Supplement), the original selection of our discovery and validation 
cohorts was based primarily on the temporal order in which they were entered into the trial. 
As presented in eTable 2 in the Supplement, without considering missing data, most clinical 
variables were balanced between the discovery and validation cohorts, except that fewer 
patients in the discovery cohort had positive lymph nodes and obstruction. The discovery 
cohort was used to identify the subtype that benefited from oxaliplatin therapy, and this 
interaction term was tested in the validation cohort.
Clinical data from the validation cohort were not available to us until we had a locked-down 
algorithm and received approval from the Protocol Review Committee of the Cancer 
Therapeutics Evaluation Program of the National Cancer Institute.
We recognized that the statistical power for the validation of this study was not optimal. 
Therefore, if the signature failed validation within C-07, we planned to use the entire C-07 
data set as a new discovery cohort for hypothesis generation. Validation would then require 
an independent data set.
Gene Expression Profiling
The C-07–customized nCounter code set (Colo-295) consisted of 295 genes selected from 
prognostic genes from our internal data and from the literature (details in eMethods 2 in the 
Supplement) plus 6 positive and 8 negative technical control genes (gene list in eTable 3 in 
the Supplement). The quality control metrics and the details of the analytical performance of 
nCounter mRNA expression profiling are shown in eMethods 3 and 4 and eFigure 1 in the 
Supplement.
Redevelopment of Subtype Identification Algorithm Using a Custom nCounter Probe Set
Because the custom nCounter assay code (Colo-295) set was designed on the basis of 
candidate prognostic genes before the publication of the articles describing intrinsic 
subtypes, only a small portion of genes in the subtype classifiers (56 of 786 genes in the 
CRCA classifier and 10 of 146 genes in the CCS classifier) were included in our nCounter 
code set. To overcome the obstacle of subtype identification caused by the limited number of 
genes, we redeveloped the CRCA classifier for the nCounter data by taking advantage of the 
publicly available gene expression microarray data from the core training data set (N = 387) 
in which the original CRCA classifier was developed by Sadanandam et al.7 Of 1262 genes 
with high dynamic range in the core training data set, 72 were included in our nCounter code 
set of 295 genes (Figure 2). Based on the expression profile of 72 genes and the original 
CRCA subtype assignment for the 387 samples in the CRCA core training data set, we 
generated the centroid using these 72 genes for each subtype using the prediction analysis of 
microarray method.13 The number of genes is selected by 10-fold cross-validation. The 
redeveloped centroids of the CRCA subtypes are presented in eTable 4 and eFigure 2 in the 
Supplement. The overall cross-validation error rate is 0.157, ranging from 0.052 for stem-
like subtype to 0.302 for gobletlike subtype (eTable 5 and eMethods 5 in the Supplement). 
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Analysis was carried out using the pamr packages implemented in R. To assign C-07 
samples to a CRCA subtype, we calculated the Spearman rank correlation between each 
sample and the redeveloped centroids for each subtype and assigned the sample to the most 
correlated subtype. Similarly, centroids were redeveloped for the CCS classifier as described 
in eMethods 6 in the Supplement and are presented in eTable 6 in the Supplement.
Statistical Analysis
Associations of clinical variables and mutations with subtypes were analyzed by means of 
the χ2 test.
The primary end point in this study was time to recurrence (time from random assignment to 
recurrence, censored for death [competing risk] or last follow-up). For each variable, we 
assessed (1) prognostic significance using univariate Cox models and (2) predictive values 
for oxaliplatin therapy benefit using Cox models with an interaction term between treatment 
and tested variable. For subtypes, we further tested prognostic value using multivariate 
analysis with adjustment for clinical variables age, sex, tumor stage, stage, grade, 
perforation, and obstruction.
In the validation cohort, the prespecified primary hypothesis to be tested was the enterocyte-
oxaliplatin interaction term in a Cox model with or without adjustment of clinical variables. 
All reported P values are 2 sided, and the statistical significance level was set to less than .
05. All statistical analyses were performed in R.
We calculated the effect sizes that would be necessary to achieve adequate power in the 
validation cohort. For the enterocyte subtype, with the present sample size (n = 70), with an 
a level of .05, the HR for oxaliplatin treatment must be less than 0.20 to achieve 80% power. 
The enterocyte-oxaliplatin interaction needed to be less than 0.30 to achieve 80% power 
(details in eMethods 7 and 8 in the Supplement).
Results
In C-07, among 2370 eligible patients with consent and follow-up, 1768 cases with available 
tumor blocks were used in this study (Figure 1). An additional 39 cases were lost to 
insufficient amount of RNA.
Prognostic and Predictive Values of Clinical Variables in the Entire C-07 Cohort
Stage, tumor stage, perforation, and obstruction are significantly associated with recurrence-
free survival, but among all analyzed clinical variables (eTable 7 in the Supplement), only 
obstruction was predictive of oxaliplatin benefit regardless of whether we examined only 
stage III or combined patients with stage II and III disease into one category (eFigure 3 in 
the Supplement). Because obstruction was not associated with oxaliplatin benefit in the 
MOSAIC trial,1 we did not pursue this observation further.
Current National Comprehensive Cancer Network (NCCN) guidelines recommend that all 
patients with stage III or high-risk stage II CRC be treated with oxaliplatin. However, 
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analysis in C-07 indicated that the NCCN guideline was not predictive for oxaliplatin benefit 
(details in eResults 1 and eFigure 4 in the Supplement).
Prognostic and Predictive Values of Subtypes in the Discovery Cohort
Using redeveloped centroids, we identified the CRCA subtypes7 and CCS subtypes.6 
Among 778 cases classifiable with CRCA, 91 (11.7%) were classified as enterocyte, 63 
(8.1%) as goblet-like, 202 (26.0%) as inflammatory, 239 as stemlike (30.7%), and 183 
(23.5%) as TA subtype. For CCS, 258 (33.2%), 200 (25.7%), and 320 (41.1%) were 
classified as CCS1, 2, and 3, respectively. Consistent with other studies,10 the CRCA 
subtype and CCS subtype were correlated with each other, suggesting that our newly 
developed classifier performed as expected; that is, most CCS1 tumors were subtyped as TA 
or enterocyte, most CCS2 tumors as inflammatory, and most CCS3 tumors as stemlike 
(eTable 8 in the Supplement). Association of subtypes and other clinical pathological 
variables was also similar to what has been found in other studies; for example, the 
inflammatory subtype was enriched with clinical variables associated with good prognosis 
(stage II, undifferentiated, deficient mismatch repair), whereas the stemlike subtype was 
enriched with clinical variables associated with poor prognosis (stage III, T3, or T4 tumor 
stage) (eTable 9 in the Supplement).
We assessed the prognostic value of subtypes. For both univariate and multivariate analysis 
with adjustment of clinical variables, time to first recurrence varied among the CCS 
subtypes and CRCA subtypes (eFigure 5 and eTables 10 and 11 in the Supplement). 
Consistent with other studies, stemlike or CCS3 was associated with the shortest time to first 
recurrence.
We further assessed the predictive value of subtypes. The CCS classifier did not identify any 
subtype with a significant benefit from oxaliplatin treatment and therefore was not pursued 
further for validation (eFigure 3 in the Supplement). For CRCA subtypes, only patients with 
the enterocyte subtype received significant benefit from oxaliplatin added to fluorouracil-
leucovorin treatment (HR, 0.32 [95% CI, 0.14–0.70]; P = .005 [N = 91]) (eFigure 6 in the 
Supplement). Further analysis suggested that oxaliplatin benefit in the enterocyte subtype 
may be restricted to patients with stage III disease (eFigure 7 in the Supplement).
Because only patients with stage III, enterocyte type tumors received benefit from 
oxaliplatin (HR, 0.22 [95% CI, 0.09–0.56]; P = .001 [N = 65]), the 4 other subtypes, 
gobletlike, inflammatory, stemlike, and TA, were combined as a nonbenefit group (HR, 0.91 
[95% CI, 0.73–1.12]; P = .36 [N = 480]) (Figure 3A and B). A significant enterocyte-
oxaliplatin interaction (interaction HR, 0.24; P = .002) was observed.
Prospectively Designed Retrospective Testing of the Predictive Value of CRCA Subtypes in 
the Validation Cohort
Among 825 classifiable cases in the validation cohort, 93 (11.3%) were classified as 
enterocyte, 79 (9.6%) as gobletlike, 203 (24.6%) as inflammatory, 239 (29.0%) as stemlike, 
and 211 (25.6%) as TA subtype.
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The prespecified primary analysis plan dictated primary comparison of oxaliplatin benefit in 
stage III patients in the enterocyte group vs all other subtypes combined (test of the 
enterocyte-oxaliplatin interaction). Tumors from 70 of 606 classifiable stage III patients 
(11.6%) were classified as enterocyte subtype. In the validation cohort, there was a 
nonsignificant finding of oxaliplatin benefit with an HR of 0.53 ([953% CI, 0.22–1.24]; P = .
14 [N = 70]) for the enterocyte subtype. In the other subtypes combined, the HR was 0.87 
([95% CI, 0.65–1.16]; P = .34 [N = 536]). The interaction between enterocyte subtype and 
oxaliplatin treatment was not significant (interaction P = .32) (Figure 3C and D).
Examination of time to recurrence for other individual subtypes revealed that stemlike 
subtype had the worst prognosis regardless of treatment as observed in the discovery cohort 
(eTable 12 in the Supplement). Patients with gobletlike (HR, 0.97 [95% CI, 3.42–2.21]; P = .
94 [N = 60]), stemlike (HR, 1.16 [95% CI, 0.76–1.80]; P = .48 [N = 185]), and TA (HR, 
0.79 [95% CI, 0.46–1.35]; P = .39 [N = 166]) subtypes did not gain significant benefit from 
oxaliplatin treatment (eFigure 8 in the Supplement). There was a nonsignificant finding of 
oxaliplatin benefit for the inflammatory subtype in the validation cohort (HR, 0.50 [95% CI, 
0.23–1.08]; P = .08 [N= 125]), but in the discovery cohort the HR was much higher (HR, 
1.09 [95% CI, 0.51–2.32]; P = .83) (eFigure 7 in the Supplement).
Therefore, we failed to validate our primary hypothesis that enterocyte subtype is a marker 
that predicts benefit from oxaliplatin therapy. Post hoc power calculation suggested that the 
power is less than 40% with the findings in the validation cohort (eMethod 8 in the 
Supplement).
Post Hoc Analyses of the Entire C-07 Cohort
According to our plan to use the entire cohort for new exploratory analysis for hypothesis 
generation in the likely case of failure to validate enterocyte-oxaliplatin interaction due to 
lack of statistical power, we analyzed the entire cohort for not only CRCA and CCS but also 
the Consensus Molecular Subtype (CMS) classifier,11 which was published after the 
approval of the validation protocol (eResults 2 in the Supplement).
As shown in Figure 4, enterocyte subtype from the CRCA classifier, CCS1 subtype from the 
CCS subtype classifier, and CMS2 from the CMS classifier were associated with benefit 
from oxaliplatin treatment. Further analysis suggested that both CCS1 and CMS2 consist of 
enterocyte and TA subtypes based on the CRCA classifier (eTable 13 in the Supplement). 
Significant benefit was seen only in the CCS1-enterocyte (HR, 0.17 [95% CI, 0.06–0.50]; P 
= .001) and the CMS2-enterocyte (HR, 0.20 [95% CI, 0.07–0.59]; P = .003) and not in the 
CCS1-TA (HR, 0.79 [95% CI, 0.51–1.23]; P = .30) or in the CMS2-TA (HR, 0.77 [95% CI, 
0.50–1.18]; P = .23). This suggests that the CRCA classifier may represent the best way to 
subclassify tumors to identify patients who will receive the greatest benefit from oxaliplatin. 
Examination of stage III patients in the entire cohort suggested significant enterocyte-
oxaliplatin benefit (interaction HR, 0.38; P = .003) (eFigure 9 in the Supplement).
We also examined the prognostic implications of each subtyping method within patients 
with stage II or stage III disease. Regardless of clinical stage, all 3 subtyping methods 
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identified similar tumors (stemlike, CCS3, and CMS4) as the worst prognostic group (P < .
001 for each) (Figure 5).
Discussion
In this prospectively designed, retrospectively tested study of molecular subtype–by–
oxaliplatin interaction, we observed a striking interaction between the enterocyte subtype 
with the CRCA classifier and oxaliplatin therapy benefit in the C-07 discovery cohort. 
However, the interaction was not statistically significant in the validation arm despite a 
nonsignificant finding in the same direction. Lack of statistical power could be one reason 
for our failure to validate the enterocyte-oxaliplatin interaction. In addition, our rederived 
classifier for CRCA did not have many robust classifier genes for enterocyte subtype, 
resulting in a high classification error rate. It is worth noting that the enterocyte subtype 
identification is inherently challenging, with a high classification error rate. Therefore, this 
subtype is bundled with the TA subtype in other subtype classification systems such as CCS 
classifier and CMS classifier.
Despite these limitations, the fact that subtype classifiers were originally developed outside 
C-07 makes it less likely that our data were overfitted. Thus, it is possible that the interaction 
of oxaliplatin therapy benefit with the enterocyte subtype could be validated with greater 
power and more genes that better defined the enterocyte subtype.
Our data also demonstrated heterogeneity of clinical outcome after fluorouracil-leucovorin 
therapy, as well as degree of benefit from the addition of oxaliplatin to fluorouracil-
leucovorin in colon cancer according to molecularly defined subtypes. In particular, the 
stemlike subtype (or equivalently CCS3 subtype in the CCS classifier and CMS4 in the CMS 
classifier) was not only associated with poor prognosis in patients treated with fluorouracil-
leucovorin but also in patients treated with oxaliplatin plus fluorouracil-leucovorin 
regardless of clinical stage. Therefore, we can conclude that C-07 data validated the poor 
prognosis of the stemlike subtype even after standard adjuvant chemotherapy in both stage II 
and III colon cancer.
The observation that patients with stemlike tumors have a poor prognosis is consistent with 
other studies, but our data demonstrate the possibility that, unlike the patients with a poor 
prognosis in breast cancer, the stemlike subtype does not receive a significant benefit from 
chemotherapy with a high residual risk even after oxaliplatin-based chemotherapy. Roepman 
et al9 demonstrated that CCS3 (ie, the stemlike subtype) is characterized by high expression 
of epithelial mesenchymal transition markers and low expression of proliferation markers 
and is resistant to adjuvant fluorouracil-leucovorin treatment, albeit in a nonrandomized 
retrospective cohort comparison. Surprisingly, the epithelial mesenchymal transition gene 
expression signature is mostly contributed by the stromal cells driven by transforming 
growth factor β signaling rather than by the cancer cells.14 Therefore, clinical and biological 
evidence suggests that stemlike subtype colon cancer is resistant to chemotherapy and 
attacking cancer cells alone may not be the optimal therapeutic approach for these tumors 
largely driven by microenvironmental interaction.
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For future clinical trials in colon cancer, it may be reasonable to stratify patients according 
to stemlike subtype, not only because of this subtype’s poor prognosis, but also because the 
stemlike subtype has been most consistently identified across all gene expression profiling 
studies and the performance of classifier genes for this subtype is robust with a low 
misclassification rate (which varies among subtypes). Therefore, the development of 
alternative therapeutic strategies for patients with the stemlike subtype of colon cancer 
should be a priority.
Conclusions
This study suggested that patients with different subtypes of colon cancer have distinct 
prognoses and may obtain differential benefit from oxaliplatin added to fluorouracil-
leucovorin therapy. Whether patients with enterocyte subtype are the only ones who derive a 
significant clinical benefit from oxaliplatin needs to be tested further in external cohorts due 
to the failure of validation in this study. To further investigate the predictive value of colon 
cancer subtypes for determining oxaliplatin therapy benefit, we plan to develop a better 
panel of genes for subtype identification, resulting in a more accurate identification of 
subtypes. Subtyping of patients with CRC may provide a rationale for the assignment of 
patients to different treatment regimens, such as oxaliplatin-based chemotherapy for patients 
with enterocyte tumors, immune checkpoint inhibitors for inflammatory cancer, anti-MUC1 
antibodies for goblet cancers, and new targeted therapies for stemlike cancers.
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Key Points
Question
Do patients with different colorectal cancer subtypes have different prognosis and do 
their responses differ with regard to treatment with oxaliplatin when it is combined with 
fluorouracil plus leucovorin?
Findings
This secondary analysis of a randomized clinical trial validated the finding that patients 
with a stemlike or Colorectal Cancer Subtype 3, or Consensus Molecular Subtype 4 have 
a poor prognosis, regardless of stage or chemotherapy regimen. The observation that 
patients with the enterocyte subtype received significant benefit from oxaliplatin was not 
validated in an independent cohort.
Meaning
This study highlights the importance of subtyping colorectal cancer with gene expression 
profiling for prognostic information and of conducting future clinical trials to test the 
clinical utility of subtyping to determine oxaliplatin treatment benefit.
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Figure 1. 
Consolidated Standards of Reporting Trials Diagram, National Surgical Adjuvant Breast and 
Bowel Project (NSABP) C-07
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Figure 2. 
Procedure for Redeveloping Colorectal Cancer Assigner (CRCA) Classifier Using 72 Genes 
Included in the nCounter Data Profiled With the Customized nCounter Code Set (Colo-295)
Song et al. Page 13
JAMA Oncol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Kaplan-Meier Plots for Recurrence-Free Survival of Stage III Patients
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Figure 4. 
Exploratory Analyses: Forest Plot of Treatment Benefit for Subtypes Identified by Different 
Classifiers for C-07 Participants With Stage III Disease
The box size is proportional to the precision. CCS indicates Colorectal Cancer Subtype; 
CRCA, Colorectal Cancer Assigner; CMS, Consensus Molecular Subtype; HR, hazard ratio; 
and TA, transit amplifying.
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Figure 5. 
Kaplan-Meier Plots for Recurrence-Free Survival of Entire Cohort (Stage II or Stage III 
Patients) According to Colorectal Cancer Assigner (CRCA), Colorectal Cancer Subtype 
(CCS), and Consensus Molecular Subtype (CMS) Subtypes
NA indicates not assignable to a subtype.
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